Cryopyrin-Associated Periodic Syndromes (CAPS)
A spectrum of rare autoinflammatory conditions driven by NLRP3 gene variants, causing recurrent fever, rash, and inflammation that respond well to targeted IL-1 blocking therapy.
- IL-1 Blockade Access
- Genetic Confirmation Support
- Specialist Rheumatology Review
- Underlying Gene
- NLRP3
- Spectrum Severity
- FCAS (Mild) โ NOMID (Severe)
- Inheritance Pattern
- Autosomal Dominant
- Advanced Therapies
- IL-1 Inhibitors (Anakinra, Canakinumab)
Condition Overview
Cryopyrin-Associated Periodic Syndromes (CAPS) describe a spectrum of rare autoinflammatory diseases caused by gain-of-function variants in the NLRP3 gene, which encodes a key component of the inflammasome โ a protein complex that triggers release of interleukin-1 beta (IL-1ฮฒ).
The spectrum ranges from Familial Cold Autoinflammatory Syndrome (FCAS), the mildest form often triggered by cold exposure, through Muckle-Wells Syndrome (MWS) of intermediate severity, to Neonatal-Onset Multisystem Inflammatory Disease (NOMID, also called CINCA), the most severe form presenting in infancy with chronic systemic inflammation.
Although individually rare, CAPS is important to recognize early because untreated chronic inflammation can lead to long-term complications such as hearing loss and amyloidosis, while targeted IL-1 blocking therapy can dramatically control symptoms and prevent organ damage.
Types and Variants
CAPS is classified along a severity spectrum, with overlapping features between adjacent forms.
Symptoms and Signs
Symptoms vary along the CAPS spectrum but share a common pattern of recurrent fever and inflammatory skin disease.
Causes and Risk Factors
CAPS is caused by overactivity of the NLRP3 inflammasome, most often due to an inherited gene variant, though some cases arise spontaneously.
Diagnosis and Investigations
Diagnosis combines a clinical pattern of recurrent fever and rash with genetic confirmation of an NLRP3 variant, supported by inflammatory marker testing.
CAPS Severity Spectrum
CAPS is classified by severity along a continuum rather than by formal stages, which guides the intensity of monitoring and treatment.
Standard Treatment Options
Treatment of CAPS has been transformed by IL-1 blocking therapy, which directly targets the underlying inflammasome pathway rather than simply suppressing symptoms.
Advanced and Emerging Treatment Options
IL-1 pathway blockade is itself considered an advanced, targeted therapy; ongoing research focuses on optimizing access, dosing, and complication prevention.
Targeted Biologic
Anakinra (IL-1 receptor antagonist)
Daily injectable that blocks IL-1 receptor signaling, often used for initial control or in younger children.
Targeted Biologic
Canakinumab (anti-IL-1ฮฒ monoclonal antibody)
Long-acting injectable given every 4โ8 weeks, widely used for sustained CAPS control across the severity spectrum.
Targeted Biologic
Rilonacept (IL-1 trap)
Weekly injectable IL-1 blocker used as an alternative for patients who need a different dosing schedule.
Precision Medicine
Genotype-guided dose optimization
Specialist centers use genetic and biomarker data to individualize IL-1 blockade dosing, particularly in NOMID.
Biomarkers and Precision Medicine
Inflammatory and genetic markers guide both diagnosis and ongoing treatment monitoring in CAPS.
When a Second Opinion May Be Important
Because CAPS is rare and treatment is highly specialized, several situations call for review by a center experienced in autoinflammatory disease.
Clinical Trials and Research
Prognosis and Key Outcome Factors
The introduction of IL-1 blocking therapy has transformed outcomes in CAPS, converting what was once a progressively damaging disease โ especially in NOMID โ into a generally well-controlled chronic condition with consistent treatment.
Supportive Care and Living With CAPS
Living with CAPS involves consistent biologic therapy alongside attention to triggers, organ monitoring, and family support.
How CancerFax Helps You Explore Treatment Options
CancerFax can help coordinate genetic and inflammatory marker report review, facilitate second opinions on IL-1 therapy response, and connect families with specialist autoinflammatory disease centers.
Get a free case reviewFrequently Asked Questions
CAPS is a spectrum of rare genetic autoinflammatory diseases caused by NLRP3 gene variants that lead to recurrent fever, rash, and systemic inflammation.
Recurrent fevers with an urticaria-like rash, often triggered by cold exposure, joint pain, and conjunctivitis are typical early signs.
Yes โ CAPS is caused by gain-of-function variants in the NLRP3 gene, usually inherited in an autosomal dominant pattern, though some cases arise from new mutations.
They represent increasing severity along the same NLRP3-driven spectrum, from mild cold-triggered FCAS to severe, neonatal-onset NOMID with CNS and skeletal involvement.
Diagnosis combines a characteristic fever-rash pattern with elevated inflammatory markers and genetic confirmation of an NLRP3 variant.
It is a class of biologic medications โ anakinra, canakinumab, and rilonacept โ that neutralize interleukin-1, the inflammatory protein driven by the overactive NLRP3 inflammasome in CAPS.
Yes โ progressive sensorineural hearing loss is a recognized feature of Muckle-Wells syndrome and NOMID, making regular hearing monitoring important.
CAPS is a lifelong genetic condition; it is not cured but can be very effectively controlled with ongoing IL-1 blocking therapy.
Genetic testing can confirm CAPS prenatally or in infancy in families with a known NLRP3 variant, and NOMID typically presents in the first weeks of life.
Yes. CancerFax can help coordinate review of genetic and inflammatory test results, facilitate second opinions on IL-1 blocking therapy response, and connect families with specialist centers experienced in autoinflammatory disease and advanced biologic access.
Get Specialist Guidance on CAPS Management
Send your genetic and inflammatory test results for specialist review and explore options for IL-1 targeted therapy.